Market Overview

Jefferies On Gilead: 'We See Better Days Ahead'

Jefferies On Gilead: 'We See Better Days Ahead'
Related GILD
IMX Dips In October, But Investors Remain Bullish
Investor Movement Index October Summary
Gilead And GS-9674 In PSC And NASH: To Itch Or Not To Itch (Seeking Alpha)

The new year has brought relief to Gilead Sciences, Inc. (NASDAQ: GILD)’s long-pressured stock, and one analyst projects a continuation in its U-shaped recovery.

The Rating

Jefferies analyst Michael Yee upgraded Gilead to Buy and raised the price target from $87 to $95.

The Thesis

Yee said he based the upgrade on upcoming pipeline catalysts:

  • The potential February approval and launch of B/T/TAF for HIV.
  • Unfactored Phase 3 GS-4997 data in 2019.
  • The 2018 launch of Kite’s Yescarta.
  • Kite’s scheduled release of BCMA myeloma data that “could surprise.”

Jefferies does not consider GlaxoSmithKline plc (ADR) (NYSE: GSK)’s upcoming GEMINI data report a major threat, and Eli Lilly and Co (NYSE: LLY)'s catalysts are set to elucidate Gilead’s value, Yee said. 

“GILD has had it tough since 2015, but we believe the worst is generally moving behind them,” the analyst said. 

Jefferies expects low guidance accounting for HCV, but the product represents less than 20 percent of revenue, Yee said. Low Street expectations are already baked in, and the story is shifting from Hepatitis C to other page-turning franchises, he said. 

“We see better days ahead: after three years of decline, consensus EPS re-grows for 2020 [and beyond] and we want to own GILD coming out of the decline and back into the recovery period." 

Price Action

At the time of publication, shares were trading up 4.47 percent at $84.82. 

Related Links:

Pharma M&A Picks Up Momentum

BofA: The Biotech Sector Is In A 'Perfect Storm' For M&A

Latest Ratings for GILD

Oct 2018Raymond JamesMaintainsStrong BuyStrong Buy
Oct 2018Cantor FitzgeraldMaintainsOverweightOverweight
Oct 2018PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: HIV JefferiesAnalyst Color Biotech Upgrades Price Target Analyst Ratings General Best of Benzinga


Related Articles (GILD + GSK)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Exeq Builds A Data Bridge To Better Spending Between Consumers And Merchants

Rosenblatt Defends Apple, Says Guidance Concerns Are 'Overblown'